U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

16-substituted-6-aza-androsten-4-ene-3-ones as 5-଱-reductase inhibitors

Patent 5741795 Issued on April 21, 1998. Estimated Expiration Date: Icon_subject October 17, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Patent References

3193554

Heterocyclic inhibitors of 5-଱-testosterone reductase
Patent #: 5302589
Issued on: 04/12/1994
Inventor: Frye, et al.

17 򳊬yl 6 azaandrost-4,6 diazo-4-ene-3-ones
Patent #: 5457098
Issued on: 10/10/1995
Inventor: Frye, et al.

Method of treating small mouth ulcers
Patent #: 5516799
Issued on: 05/14/1996
Inventor: Alliger

Synthesis of 6-azaandrostenones
Patent #: 5541322
Issued on: 07/30/1996
Inventor: Fang, et al.

Combination method of treating acne using 4-AZA-5଱-cholestan-ones and 4-AZA-5଱-androstan-ones as selective 5଱-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
Patent #: 5543417
Issued on: 08/06/1996
Inventor: Waldstreicher

5547957

Methods of treating androgenic alopecia with finasteride [17ଲ-N-mono-substituted-carbamoyl-4-aza-5-଱-androst-1-en-ones]
Patent #: 5567708
Issued on: 10/22/1996
Inventor: Rasmusson, et al.

Methods of treating androgenic alopecia with finasteride [17ଲ-N-mono-substituted-carbamoyl-4-aza-5-଱-androst-1-en-ones]
Patent #: 5571817
Issued on: 11/05/1996
Inventor: Rasmusson, et al.

Stimulation of hair growth with minoxidil and a 5଱-reductase inhibitor Patent #: 5578599
Issued on: 11/26/1996
Inventor: Diani, et al.

Inventors

Assignee

Application

No. 732953 filed on 10/17/1996

US Classes:

514/284, Tetracyclo ring system having the six-membered hetero ring as one of the cyclos514/253.02, Polycyclo ring system having the additional six-membered nitrogen hetero ring as one of the cyclos514/256, 1,3-diazines (e.g., pyrimidines, etc.)514/263.22, The additional hetero ring is six-membered consisting of one nitrogen and five carbons514/269, Pyrimidines with chalcogen bonded directly to a ring carbon of said pyrimidine moiety540/4, Boron or silicon containing544/264, Purines (including hydrogenated)544/265, Chalcogen bonded directly to ring carbon of the purine ring system544/298, Chalcogen bonded directly to diazine ring carbon546/14, Silicon containing546/61Tetracyclo ring system having the six-membered hetero ring as one of the cyclos

Examiners

Primary: Daus, Donald G.

Attorney, Agent or Firm

Foreign Patent References

  • WP 93/13124 WO. 07/13/1993
  • WO 94/21614 WO. 09/13/1994
  • WO 95/02607 WO. 01/13/1995
  • WO 95/11254 WO. 04/13/1995
  • WO 96/11939 WO. 04/13/1996
  • WO 96/30391 WO. 10/13/1996

International Class

A61K 031/715

Abstract

Compounds of the formula I ##STR1## are inhibitors of 5଱-reductase, and are useful for the treatment of hyperandrogenic disorders such as acne vulgaris, seborrhea, female hirsutism, male pattern baldness, prostatic carcinoma, prostatitis and benign prostatic hyperplasia.

Other References

  • Fryg, Jour. Med. Chem., vol. 38, pp. 2621-2627, 1995
  • Stinson, Chem & Eng'r News Jun. 29, 1992 pp. 7, 8
  • Helliker, Wall St. Jour. Jun. 7, 1991 pp. A1, A7
  • Diani et al., Jour. Clin. Endo. & Metab. vol. 74 pp. 345-350, 199
PatentsPlus Images
Enhanced PDF formats
loading...
PatentsPlus: add to cart
PatentsPlus: add to cartSearch-enhanced full patent PDF image
$9.95more info
 
Sign InRegister
Username  
Password   
forgot password?